Neutrophil–Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer
نویسندگان
چکیده
منابع مشابه
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
Triple-negative breast cancer (TNBC) constitutes a heterogeneous breast cancer subgroup with poor prognosis; survival rates are likely to be lower with TNBC compared to other breast cancer subgroups. For this disease, systemic adjuvant chemotherapy regimens often yield suboptimal clinical results. To improve treatment regimens in TNBC, identification of molecular biomarkers may help to select p...
متن کاملPathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer
PURPOSE Our goal was to determine the impact of pathologic response after neoadjuvant chemotherapy in triple negative breast cancer (TNBC) on the subsequent risk of locoregional recurrence (LRR) and disease-free survival (DFS) in the setting of adjuvant radiation therapy. METHODS AND MATERIALS This was an institutional review board-approved retrospective chart review of patients with clinical...
متن کاملthe assessment of response to adjuvant chemotherapy with cmf in triple negative breast cancer.
introduction: breast cancers are divided into at least 4 sub types on the basis of gene expression profiles and expression of receptors as measured by ihc (immunohistochemical). triple negative breast cancer (tnbc) is more chemosensitive yet, it is much harder to detect than other sub types. at present lack of highly effective therapeutic targets for tnbc, leaves standard chemotherapy, as the o...
متن کاملMetronomic chemotherapy for triple negative breast cancer?
Despite the incidence for women older than 70 years being 33%, they are usually excluded from screening schedules and clinical trials. Furthermore, about 15% of breast cancers in older patients are of the triple-negative subtype (TNBC), which is known to be an aggressive histological subtype with very limited treatment options available, and associated with a very poor prognosis [1]. Indeed, th...
متن کاملPromoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
BACKGROUND BRCA1 function is inactivated through BRCA1 promoter methylation in a substantial number of triple-negative breast cancers. We investigated the impact of BRCA1-methylation status on the efficacy of adjuvant chemotherapy in patients with triple-negative breast cancer or with non-triple-negative breast cancer. METHODS BRCA1 promoter methylation was assessed in 1163 unselected breast ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2018
ISSN: 1718-7729
DOI: 10.3747/co.25.3888